EvaluatePharma views lumateperone as the third-biggest potential new
drug approval ahead in the back half of 2019.
The US Food and Drug Administration (FDA) has granted investigational new
drug approval (IND) to France-based Sensorion to proceed with SENS-401, based on preclinical data and clinical development plan, it was reported yesterday.
"New chemical entities are required to go through the full
drug approval process which requires demonstration of safety and efficacy," said CEO Patrick McEnany.
Overall, about 70% of speakers (76 out of 112) supported
drug approval, the study found.
Overall, about 70% of speakers (76 out of 112) supported
drug approval. Speakers who disclosed a conflict of interest were significantly more likely to support
drug approval.
Roughly a decade ago, the FDA created accelerated ("fast-track")
drug approval pathways to get drugs for rare, life threatening conditions to patients faster.
We all need a
drug approval process that delivers good decisions based on adequate evidence.
Hamburg pushed to speed up the
drug approval process and proposed measures to improve nutrition, like limiting trans-fats in foods and posting calorie counts on restaurant menus.
According to a representative from InterVest, a Korea-based VC firm that manages the Fund, CrystalGenomics' potential had already been recognized by the Korean government in the summer of 2012 when it became one of the 43 companies to be designated as the Korea Innovative Pharmaceutical Company (KIPC) and only 2 years later, CrystalGenomics is now on track to become the first bio venture company from Korea to obtain a new
drug approval, which is unprecedented in the industry.
There's an urgent need for innovative new drugs, especially for the treatment of "antibiotic-resistant infections and rare pediatric disease." Policymakers have already done much to speed innovation; the focus now is on pouring more money into research and speeding the
drug approval process.
As part of the National Multiple Sclerosis Society's annual Public Policy Conference, more than 300 MS activists went to Washington, D.C., on March 6 to urge Congress to preserve funding for MS research and
drug approval.